GUIDANCE DOCUMENT
Assessment of Pressor Effects of Drugs Guidance for Industry May 2018
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-2018-D-1636
- Issued by:
-
Guidance Issuing OfficeCenter for Drug Evaluation and Research
The purpose of this guidance is to advise sponsors on the premarketing assessment of a drug’s effect on blood pressure. Elevated blood pressure is known to increase the risk of stroke, heart attack, and death. The effect of a drug on blood pressure can therefore be an important consideration in benefit-risk assessment.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2018-D-1636.